141 related articles for article (PubMed ID: 33591859)
1. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.
Phiri K; Hallas J; Linder M; Margulis A; Suehs B; Arana A; Bahmanyar S; Hoffman V; Enger C; Horter L; Odsbu I; Olesen M; Perez-Gutthann S; Kristiansen NS; Appenteng K; de Vogel S; Seeger J
Curr Med Res Opin; 2021 May; 37(5):867-877. PubMed ID: 33591859
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Hoffman V; Hallas J; Linder M; Margulis AV; Suehs BT; Arana A; Phiri K; Enger C; Horter L; Odsbu I; Olesen M; Perez-Gutthann S; Xu Y; Kristiansen NS; Appenteng K; de Vogel S; Seeger JD;
Drug Saf; 2021 Aug; 44(8):899-915. PubMed ID: 34236595
[TBL] [Abstract][Full Text] [Related]
3. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
4. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
Bunniran S; Davis C; Kristy R; Ng D; Schermer CR; Uribe C; Suehs BT
Neurourol Urodyn; 2018 Jan; 37(1):177-185. PubMed ID: 28370541
[TBL] [Abstract][Full Text] [Related]
5. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR
Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk profile in individuals initiating treatment for overactive bladder - Challenges and learnings for comparative analysis using linked claims and electronic medical record databases.
Vonesh E; Gooch KL; Khangulov V; Schermer CR; Johnston KM; Szabo SM; Rumsfeld JS
PLoS One; 2018; 13(10):e0205640. PubMed ID: 30325968
[TBL] [Abstract][Full Text] [Related]
9. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
Chapple CR; Siddiqui E
Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
[TBL] [Abstract][Full Text] [Related]
10. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
[TBL] [Abstract][Full Text] [Related]
11. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study.
Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Hairston JC
Low Urin Tract Symptoms; 2021 Oct; 13(4):425-434. PubMed ID: 33987973
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH
BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
[TBL] [Abstract][Full Text] [Related]
15. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.
Hakimi Z; Nazir J; McCrea C; Berling M; Fatoye F; Ramos B; Wagg A
J Med Econ; 2017 Jun; 20(6):614-622. PubMed ID: 28286993
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.
Katoh T; Igawa Y; Yamaguchi O; Kato D; Hamada T; Kuroishi K
Low Urin Tract Symptoms; 2020 Jan; 12(1):68-80. PubMed ID: 31571403
[TBL] [Abstract][Full Text] [Related]
18. A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study).
Ko KJ; Choo MS; Chang YS; Kim JC; Lee KS
Neurourol Urodyn; 2020 Nov; 39(8):2417-2424. PubMed ID: 32894793
[TBL] [Abstract][Full Text] [Related]
19. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
Wagg A; Nitti VW; Kelleher C; Castro-Diaz D; Siddiqui E; Berner T
Curr Med Res Opin; 2016; 32(4):621-38. PubMed ID: 26828974
[TBL] [Abstract][Full Text] [Related]
20. Mirabegron: A Review in Overactive Bladder Syndrome.
Deeks ED
Drugs; 2018 Jun; 78(8):833-844. PubMed ID: 29869204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
